Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)

NCT04452591 is registered in ClinicalTrials.gov with CG Oncology, Inc. as lead sponsor.

NCT NCT04452591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04452591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)
Lead sponsor
CG Oncology, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 27, 2020
Completion date
December 24, 2031
Enrollment
190 (estimated)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade ta/ t1 papillary disease bladder cancer, non muscle invasive bladder cancer